[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-mellitus-dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-mellitus-dm":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,64,97,119,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":40,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100650085","health-for-hungary-h4h---longitudinal-collection-of-blood-samples-and-corresponding-data-100650085",false,"NCT07743021","Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data","Health for Hungary - Longitudinal Collection of Blood Samples and Corresponding Data for Longterm Evaluation of Innovative Diagnostic Techniques in Subjects Without Clinically Relevant Disorders at Baseline to Institute Molecular Fingerprinting Reference Norms","H4H","Low- and Moderate-risk Cohort:\n\nInclusion Criteria:\n\n1. Signed informed consent form (ICF) of the study.\n2. Age \\> 40 years.\n3. Willingness to fill in the study questionnaire.\n4. No clinically relevant symptoms as assessed by the investigator, subjects with existing medical conditions may be eligible given that they are symptom free and that full treatment of the condition is medically confirmed.\n5. Willingness to participate in future visits.\n\nExclusion Criteria:\n\n1. Self-reported pregnancy (no test).\n2. Indications of clinically relevant medical conditions in self-reported healthy subjects.\n3. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure.\n4. Any conditions preventing blood-draw.\n5. Vulnerable subjects.\n6. Foreseeable lack of compliance.\n7. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject.\n8. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and \u002F or further pharmaceutical product administration is planned.\n9. Vaccination within the last 14 days.\n\nHigh-risk Cohort:\n\nInclusion Criteria:\n\n1. Signed informed consent form (ICF) of the study.\n2. Age \\> 50 years.\n3. Willingness to fill in the study questionnaire.\n4. Willingness to participate in future visits and medical investigations, the presence of at least 2 of the following 3 risk factors (inclusion criteria #5-7):\n5. Hypertension, receiving antihypertensive treatment.\n6. Dyslipidemia\u002F Hypercholesterolemia (\\>5.2mmol\u002FL total cholesterol level), on or not on statin-treatment.\n7. Active or former smoker, with smoking history of at least 20 pack-years, and\u002For the presence of intermediate lung nodule on prior LDCT testing.\n8. No clinically relevant symptoms as assessed by the investigator; subjects with existing medical conditions may be eligible given that they are symptom free and that treatment of the condition is well documented.\n\nExclusion Criteria:\n\n1. Self-reported pregnancy (no test).\n2. Cardiovascular disease (including obstructive coronary artery disease, peripheral artery disease, aortic aneurysm) or other clinically significant heart disease (congenital, valvular heart disease, cardiomyopathy, heart failure and heart disease requiring ICD \\[implantable cardioverter defibrillator\\] or pacemaker therapy).\n3. Interstitial lung disease or severe COPD (chronic obstructive pulmonary disease) in GOLD stages 3 or 4.\n4. Active cancer or malignant disease with less than 5 years history of remission.\n5. Indications of clinically relevant medical conditions in self-reported healthy subjects, especially if (a) the condition requires regular or constant specialist checkups, or (b) pharmacological therapy indicates the presence of significant NCDs or multimorbidity, i.e., chronic polypharmacy (use of 5 or more medications at enrollment or over the last 6 months), or drug therapy necessitating a specialist input for initiation or management (e.g., combined anti-diabetic treatment with two or more medications).\n6. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure.\n7. Any conditions preventing blood-draw or CT scans.\n8. Vulnerable subjects.\n9. Foreseeable lack of compliance.\n10. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject. 'High-risk' subjects enrolled in the low- and moderate-risk arm of the H4H study might be reallocated to the high-risk study arm after the first 4-5 visits.\n11. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and\u002For further pharmaceutical product administration is planned.\n12. Vaccination within the last 14 days of sample collection.",true,"ALL","40 Years",{"count":21,"type":22},15000,"ESTIMATED","OBSERVATIONAL","The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants.\n\nIndications Studied:\n\nApparently healthy, symptom-free participants are enrolled and followed up to study the onset of new-onset diseases with special emphasis on non-communicable diseases (NCDs).\n\nStudy Design:\n\nSingle-country, multicenter, prospective, longitudinal survey.\n\nObjectives:\n\nThe study aims to establish reference ranges of blood parameters using routine clinical blood tests and high-information-content methods, including proteomics, metabolomics and the so-called infrared molecular fingerprinting.\n\nThe study also aims to identify novel biomarkers of major non-communicable diseases, including atherosclerotic cardiovascular disease, cancer, diabetes and chronic respiratory disease.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Non-communicable Diseases (NCD)","Neoplams","Cancer","Lung Cancer (NSCLC)","Cardiovascular Diseases (CVD)","Atherosclerotic Cardiovascular Disease (ASCVD)","Peripheral Artery Disease (PAD)","Coronary Artery Disease (CAD)","Stroke (CVA) or TIA","Diabetes Mellitus (DM)","Type 2 Diabetes (T2DM)","Prediabetes","Chronic Respiratory Diseases","Chronic Obstructive Pulmonary Disease (COPD)",[41,42,43,44,45,46,47,48,49,50],"Personalized health","Molecular fingerprints","Longitudinal health monitoring","Early-stage disease detection","Innovative research platforms","Precision care","Proteomics","Metabolomics","in vitro diagnostics","Prevention medicine","RECRUITING","2026-07-29",{"date":54,"type":55},"2026-08-03","ACTUAL",{"date":57,"type":55},"2021-07-27",{"date":59,"type":22},"2030-12-31",{"name":61,"class":62},"Center for Molecular Fingerprinting Research Nonprofit LLC","OTHER",33,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":18,"minAge":71,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100628745","evaluating-the-efficacy-of-pulsating-electromagnetic-field-therapy-by-crad-ulcer-x-01-for-diabetic-foot-ulcers-100628745","NCT07465640","Evaluating the Efficacy of Pulsating Electromagnetic Field Therapy by CRAD ULCER X-01 for Diabetic Foot Ulcers","Evaluating the Efficacy of Pulsating Electromagnetic Field (PEMF) Therapy for Diabetic Foot Ulcers Using the CRAD ULCER X-01 Device: A Randomised Parallel-Group Pilot Study","Inclusion Criteria:\n\n* Provision of written consent by subjects.\n* Subject of either sex.\n* At least 18 years of age.\n* Known diabetes mellitus.\n* Diagnosed with chronic DFU Grade I-III and Stage A according to the University of Texas Classification as recommended in the Malaysian Clinical Practice Guidelines for the Management of Diabetic Foot (2nd Edition).\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide written consent.\n* Inability or unwillingness to comply with the requirements of the protocol as determined by the investigator.\n* Other medical conditions which, in the investigator's judgement, may be associated with increased risk to the subject or may interfere with study assessments or outcomes.\n* Participation in another clinical trial and\u002For recipient of investigational therapy within 4 weeks prior to screening visit.\n* Patients who have metal implants in any part of the body.\n* Patients with a pacemaker.\n* History of malignancies.\n* Presence of chronic kidney disease co-morbidity.\n* Presence of severe peripheral artery disease, assessed when the ankle-brachial index (ABI) is \\\u003C0.40.","18 Years",{"count":73,"type":22},32,"INTERVENTIONAL",[76],"NA","Background: Diabetic foot ulcer (DFU) is a frequent complication of chronic, uncontrolled diabetes mellitus (DM). Treatment with antibiotics, daily dressing, wound debridement, and wound off-loading is often prescribed. However, many DFU patients still progress into severe outcomes, including non-healing of wounds, infections, necrosis, and osteomyelitis. Prior research has shown that the application of pulsating electromagnetic field (PEMF) could accelerate wound healing, including in those afflicted with DFUs. Therefore, this study aimed to evaluate the efficacy of a locally developed CRAD ULCER X-01 device that uses the principles of PEMF in promoting DFU healing. Methods: A total of 32 patients with chronic, non-healing DFUs will be recruited from the Orthopaedic Clinic of Hospital Angkatan Tentera Tuanku Mizan and divided into control (C) (n=8) and treatment (T) (n=24) groups. All patients will receive a standard daily dressing. The PEMF will be supplemented for 1 hour\u002Fday, 2 hours\u002Fday, and 3 hours\u002Fday for T1, T2, and T3 subgroups, respectively (n=8 per group); whereas the C group will be controlled for placebo effect (device in-place but switched off). The therapy duration will be until the wound is closed or for a maximum period of three months. All patients will undergo wound assessment, wound edge tissue histology by haematoxylin and eosin (H\\&E) staining, and immunohistology (for vascular endothelial growth factor \\[VEGF\\] and fibroblast growth factor 2 \\[FGF-2\\] expression), as well as serum superoxide dismutase (SOD) and C-reactive protein (CRP) at preand post-treatment, along with glycated haemoglobin (HbA1c) measurement only at post-treatment to control for confounder (i.e., glucose control for the past three months). This study hypothesizes that PEMF therapy by CRAD ULCER X-01 device will accelerate DFU healing and improve tissue integrity, with minimal systemic effects assessed via oxidative stress and inflammatory markers. Conclusion: The results from this study will validate PEMF's effectiveness in promoting DFU healing and establish the potential use of locally developed CRAD ULCER X-01 devices as supplementary therapy to standard DFU care.",[79,35],"Diabetic Foot Ulcer",[81,82,83,84,85,86],"pulsating electromagnetic field","wound healing","oxidative stress","inflammation","diabetic foot ulcer","diabetes mellitus","2026-07-27",{"date":89,"type":55},"2026-07-28",{"date":91,"type":55},"2026-06-01",{"date":93,"type":22},"2027-09-01",{"name":95,"class":62},"National Defence University of Malaysia",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":74,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":96},"100646061","pulsed-electromagnetic-field-therapy-for-diabetic-foot-ulcer-sensation-100646061","NCT07696728","Pulsed Electromagnetic Field Therapy for Diabetic Foot Ulcer Sensation","Effect of Low Frequency Pulsed Electromagnetic Field Therapy on Vibration Perception Threshold and Protective Sensation in Diabetic Foot Ulcer","Inclusion Criteria:\n\n* Participants must have a clinical diagnosis of Type 2 diabetes (HbA1c ≥ 6.5) (Bolen et al., 2016).\n* Patients with Wagner grade 1 diabetic foot ulcers was selected.\n* Michigan Neuropathic Screening Instrument history score ≤7 (Viswanathan et al., 2025).\n* Participants showing reduced vibration perception threshold on 128Hz Tunning fork was included to confirm the presence of sensory neuropathy Associated with diabetic ulcers (Viswanathan et al., 2025).\n* Sensation on 10g monofilament less then 8 point out of 10 indicate reduces Sensation.\n* Participants having diabetes for more than 10 years (Grewal et al., 2015).\n* Pariticipants aged between 40 to 60 years.\n* Both gender were included.\n* Participants who was willing to give consent.\n\nExclusion Criteria:\n\n* Participants who have significant cognitive impairment (e.g Dementia, Alzheimer) that would prevent them from understanding and adhering to Study instructions.\n* Participants with active infections requiring systemic antibiotic therapy (Kwan et al., 2015).\n* Patients with comorbidities such as malignancy, severe renal disease, or Other systemic condition.\n* Participants who was not taking any medicine","60 Years",{"count":106,"type":22},42,[76],"Diabetes Mellitus (DM) is a chronic metabolic disorder characterized by hyperglycaemia for extended periods of time, which causes damage to peripheral nerves, resulting in sensory, motor and autonomic dysfunction. The study will aim to assess the effect of the Low pulse electromagnetic field therapy in VPT and protective sensation in the diabetic foot ulcer. The total number of participants will be 42 (calculated by epi tool) and the participants are to be divided among two groups. Non Probability Consecutive sampling technique will be used for this study.\n\nThe data collection tools will be Wagner Classification System for Diabetic Foot Ulcers, Numerical Pain Rating Scale, Goniometry, 10 g monofilament, Tuning Fork 128 Hz will be used. After meeting the inclusion and exclusion criteria and taking the written and verbal informed consent participants in one group will receive (low frequency pulsed electromagnatic field therapy and ankle Range of Motion) and other group will be receive (Sham PEMF and ankle Range of motion). Both interventions will be given three times weekly (or every other day) for 6 weeks. Vibrations perception, protective sensation, pain, ankle ROM and will be the outcome measures of the study. The data will be collected at baseline and 6 weeks. The data will be analyzed by using SPSS 23 and interpreted by using MS Word.",[35],"2026-07-09",{"date":112,"type":55},"2026-07-10",{"date":114,"type":22},"2026-07-07",{"date":116,"type":22},"2026-08-05",{"name":118,"class":62},"University of Faisalabad",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":17,"sex":18,"minAge":126,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":74,"phases":129,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100626214","this-study-is-conducted-to-evaluate-the-18-month-clinical-performance-of-complete-bioactive-restorative-system-for-occlusal-restorations-between-diabetic-and-non-diabetic-patients-100626214","NCT07432724","This Study is Conducted to Evaluate the 18-month Clinical Performance of Complete Bioactive Restorative System for Occlusal Restorations Between Diabetic and Non-diabetic Patients.","A Prospective Clinical Evaluation of Bioactive Restorative System in Controlled Diabetic and Non Diabetic Patients: An 18-Month Non-Randomized Comparative Study.","Inclusion Criteria:\n\n* Patients indicated for a Class I posterior composite restoration\n* permanent tooth\n* ICDAS 3 or 4\n\nExclusion Criteria:\n\n* uncontrolled diabetic patients\n* primary dentition\n* special needs","20 Years",{"count":128,"type":22},50,[76],"This study is conducted to evaluate the 18-month clinical performance of complete bioactive restorative system for occlusal restorations between diabetic and non-diabetic patients.",[35],[133],"Bioactive composite","NOT_YET_RECRUITING","2026-02-24",{"date":137,"type":55},"2026-02-25",{"date":139,"type":22},"2026-08-01",{"date":141,"type":22},"2028-04-01",{"name":143,"class":62},"Cairo University",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":17,"sex":18,"minAge":71,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":96},"100617261","central-sensitization-in-painful-and-painless-diabetic-peripheral-neuropathy-100617261","NCT07316322","Central Sensitization in Painful and Painless Diabetic Peripheral Neuropathy","Comparison of Central Sensitization in Painful and Painless Diabetic Peripheral Neuropathy Phenotypes: A Multidimensional Psychophysiological Assessment","Inclusion Criteria:\n\n* Being between 18 and 80 years of age\n* Having a diagnosis of Type 2 diabetes mellitus for at least 1 year\n* Providing written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Non-diabetic causes of polyneuropathy (alcohol, chemotherapy, vitamin deficiencies, renal failure, hypothyroidism, etc.)\n* Active ulcer, infection, or severe vascular insufficiency in the lower extremity\n* Central nervous system disorders (stroke, multiple sclerosis, spinal cord injury, etc.)\n* Skin lesions, dermatitis, wounds, or infection in the test areas (foot or forearm)\n* Peripheral entrapment neuropathies or related radiculopathies (e.g., carpal tunnel syndrome, C7-C8 radiculopathy)\n* Chronic widespread pain syndrome (fibromyalgia, etc.) or active flaring rheumatologic disease\n* Dose change within the last 2-4 weeks in medications affecting pain modulation (gabapentinoids, SNRI\u002FTCA, opioids, hypnotics, etc.)","80 Years",{"count":153,"type":22},128,"This research is structured as a cross-sectional observational study. The primary objective is to compare central sensitization across painful and painless phenotypes of diabetic peripheral neuropathy. The study will be conducted among individuals diagnosed with type 2 diabetes mellitus at the Department of Geriatrics, İnönü University Turgut Özal Medical Center. All assessments will be administered in accordance with a rigorously standardized protocol.\n\nEligible participants will include individuals aged 18 to 80 years who have had a confirmed diagnosis of type 2 diabetes mellitus for at least one year, are capable of comprehending and following verbal instructions in Turkish required for the study procedures, and provide written informed consent.\n\nAll statistical analyses will be performed using IBM SPSS Statistics (v.29, Armonk, NY, USA) and JASP (v.0.18, Amsterdam, Netherlands).",[35],[157,158,159,160],"Diabetus Mellitus","Central sensitization","Temporal summation","Neuropathic pain","2026-01-01",{"date":163,"type":55},"2026-01-05",{"date":165,"type":22},"2025-12-15",{"date":167,"type":22},"2026-09-15",{"name":169,"class":62},"Inonu University"]